Mårten Winge new CEO

Uppsala, April 28, 2021: STRIKE Pharma, (“STRIKE”) a Swedish start-up focused on personalized immunotherapy today announced the appointment of Pyrosequencing and Olink veteran Mårten Winge as CEO. Founded in 2020 out of Uppsala University, STRIKE’s vision is to provide an affordable and scalable personalized immunotherapy to treat solid tumors by commercializing the proprietary Immune Gas Pedal technology (IMMGAP).

IMMGAP is based on research by Associate professor Sara Mangsbo at Uppsala University and has been co-developed with the SciLifeLab’s Drug Discovery and Development Platform. While the primarily focus is on cancer, the technology has the potential to become a generic delivery method for any type of disease. Winge has a Master of Science in Molecular Biology from Karolinska Institute, and over the past twenty years he has held executive management and board positions at Pyrosequencing, Olink, Halo Genomics and Proxeon. Most recently he was CEO of Cartana AB, which was acquired by 10x Genomics. He is currently on the board of Countagen and Inhalation Sciences, acts as an advisor to Inossia, and is a business coach for Uppsala Innovation Center. “IMMGAP effectively utilizes our own bodies as factories to produce immune cells that can later be used to eliminate tumors. Our ambition is to transform how individualized cancer therapies are being developed,” says Mangsbo. “Mårten has extensive experience of international marketing and business development, and commercializing new technology in life science, primarily in start-up and early growth companies. His business skills and experience will enable STRIKE Pharma to move into the next phase of business and corporate development. I am pleased to welcome him onboard.” “I am delighted to have the opportunity to work with this extraordinarily talented and knowledgeable team of individuals. I believe that STRIKE Pharma is remarkably well positioned to have a major impact on the rapidly developing field of precision medicine and future individualized treatments,” commented Winge. With Mårten as CEO, Wing Cheng, previous CEO, will focus on quality assurance, regulatory compliance and market access to enable IMMGAP’s successful transition into clinical use. The team has also been strengthened by the scientific advisor Associate professor Johan Botling, who will provide expert advice on the clinical entry road ahead based on his experience implementing molecular diagnostics for tailored cancer therapies and immune oncology for the last 15 years.